UL Solutions heads into its May 5 Q1 earnings with options traders at their most defensive in months.
The options market is sounding a clear caution signal. The put/call ratio has climbed to 2.51 — well above its 20-day average of 1.74 — and has been rising steadily for two weeks. That puts it 1.5 standard deviations above the recent norm, with the pace of shift notable: the PCR was sitting near 1.17 as recently as early April before nearly doubling. The 52-week high is 3.02, so the market hasn't yet hit peak defensive positioning, but the trend is unambiguous. Meanwhile, the stock itself has held up: it closed at $91.60 on May 1, up about 7% over the past month and up 15% year-to-date, leaving it hovering close to the consensus analyst price target of $93.57.
Short positioning tells a notably different story. Bears have been covering, not building. Short interest as a percentage of free float dropped sharply over the past month — down roughly 27% — to 4.4% of the float. The ORTEX short score eased from around 45 to just above 40 between April 22 and April 24, as shorts cleared more than a million shares in a single session. Borrowing conditions are almost irrelevantly relaxed: the cost to borrow is just 0.50%, and borrow availability remains loose, with the 52-week utilization peak well behind at 19.5% in late March. There is no sign of short-side conviction here.
The bull-bear debate for UL Solutions turns on the durability of its position in the testing, inspection, and certification market. Bulls point to brand strength and the steady demand dynamics of a fragmented TIC industry where UL's scale and reputation drive pricing power. On the earnings growth side, the forward EPS momentum rank is in the 96th percentile — the highest available signal in this dataset — suggesting the Street has been lifting estimates heading in. Wells Fargo holds an Overweight with a $102 target, and BofA maintained its Buy after the February print when it raised its target to $96. The bear case centres on regulatory risk — a shift away from mandated certification requirements would cut directly into revenue — and the roughly 24% of revenue tied to China, where trade frictions remain a live variable. The majority of the coverage, however, sits at Hold, with JP Morgan and UBS both neutral at targets in the $88-$90 range, capped just below where the stock is already trading.
The February print is worth noting in context. After Q4 results, the stock surged more than 12% in a single session and held most of that gain over the following week. That reaction reset expectations; the stock has since been grinding higher from a materially higher base, and the current PE of ~39.5x reflects that re-rating. Tuesday's print will test whether organic revenue growth and margin execution can justify that premium — and whether the China exposure has widened or narrowed as a risk.
See the live data behind this article on ORTEX.
Open ULS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
